论文部分内容阅读
目的 :总结米非司酮在妇产科疾病治疗中的实施价值以及不良反应问题。方法 :对我院2016年妇科收治70例患者临床资料进行回顾分析,综合治疗方案不同,分为采取常规方法治疗的参照组(30例)、采取米非司酮治疗的实验组(40例)。对比两组妇科疾病患者的治疗效果以及药物不良反应发生率。结果 :实验组妇科疾病患者治疗总有效率为97.5%,药物不良发生率为5%;参照组妇科疾病患者治疗总有效率为80%,药物不良发生率为23.3%。经计算,组间指标数据差异有统计学意义,P<0.05。结论 :米非司酮治疗妇产科疾病疗效确切、不良反应低,符合患者治疗需求,建议推广实施。
OBJECTIVE: To summarize the value of mifepristone in the treatment of obstetrics and gynecology diseases and its adverse reactions. Methods: The clinical data of 70 patients with gynecology admitted to our hospital in 2016 were analyzed retrospectively. According to the different treatment regimens, the patients were divided into the reference group (30 cases) treated by routine method and the experimental group (40 cases) treated with mifepristone . Comparison of two groups of patients with gynecological diseases and the incidence of adverse drug reactions. Results: In the experimental group, the total effective rate of treatment for gynecological diseases was 97.5% and the rate of adverse drug reactions was 5%. The total effective rate of treatment for gynecological diseases was 80% and the rate of adverse drug reactions was 23.3%. After calculation, the difference between the index data of the groups was statistically significant, P <0.05. Conclusion: Mifepristone is effective in treating obstetrics and gynecology diseases with low adverse reactions, which meets the needs of patients’ treatment and is recommended to be popularized and implemented.